Merck Lands FDA Approval for Kidney Cancer Treatment Amid Warning Signs

Merck and Eisai have received FDA approval for Welireg plus Lenvima in previously treated advanced clear cell renal cell carcinoma. This new regimen is cleared for adults whose kidney cancer progressed after prior PD-1 or PD-L1 inhibitor therapy.

The approval is based on Phase 3 trial data that regulators used to support the use of the combination in the post-immunotherapy setting.

Welireg plus Lenvima opens a fresh chapter for Merck in advanced kidney cancer, but there are also warning signs for the company. In fact, analysis reveals five potential red flags.

Merck is expanding its oncology footprint alongside broader work across treatments, vaccines, and other healthcare products worldwide. The company's market value is around $367.1 billion.